Related references
Note: Only part of the references are listed.The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey
Sean M. Smith et al.
NEUROPHARMACOLOGY (2013)
Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats
Wei-li Chang et al.
BRAIN RESEARCH (2012)
Mouse pharmacological models of cognitive disruption relevant to schizophrenia
Jared W. Young et al.
NEUROPHARMACOLOGY (2012)
PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
Jan Kehler et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Mechanisms for the modulation of dopamine D1 receptor signaling in striatal neurons
Akinori Nishi et al.
FRONTIERS IN NEUROANATOMY (2011)
A Possible Role for the Striatum in the Pathogenesis of the Cognitive Symptoms of Schizophrenia
Eleanor H. Simpson et al.
NEURON (2010)
Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A
Christine A. Strick et al.
NEUROPHARMACOLOGY (2010)
Pergolide Treatment of Cognitive Deficits Associated with Schizotypal Personality Disorder: Continued Evidence of the Importance of the Dopamine System in the Schizophrenia Spectrum
Margaret M. McClure et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists
Brooke M. Roberts et al.
PSYCHOPHARMACOLOGY (2010)
The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats
Vera Bubenikova-Valesova et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2009)
Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to d-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons
Florence Sotty et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
Steven M. Grauer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Striatal Medium-Sized Spiny Neurons: Identification by Nuclear Staining and Study of Neuronal Subpopulations in BAC Transgenic Mice
Miriam Matamales et al.
PLOS ONE (2009)
Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine
M. Weber et al.
PSYCHOPHARMACOLOGY (2009)
Emerging drugs for schizophrenia
Ofer Agid et al.
EXPERT OPINION ON EMERGING DRUGS (2008)
Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2
Hiromi Sano et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Distinct Roles of PDE4 and PDE10A in the Regulation of cAMP/PKA Signaling in the Striatum
Akinori Nishi et al.
JOURNAL OF NEUROSCIENCE (2008)
Preclinical characterization of selective phosphodiesterase 10A inhibitors: A new therapeutic approach to the treatment of schizophrenia
C. J. Schmidt et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
The antipsychotic potential of l-stepholidine -: a naturally occurring dopamine receptor D1 agonist and D2 antagonist
Sridhar Natesan et al.
PSYCHOPHARMACOLOGY (2008)
Realistic expectations of prepulse inhibition in translational models for schizophrenia research
Neal R. Swerdlow et al.
PSYCHOPHARMACOLOGY (2008)
D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons
D. James Surmeier et al.
TRENDS IN NEUROSCIENCES (2007)
Inhibition of the striatum-enriched phosphodiesterase PDEIOA: A novel approach to the treatment of psychosis
Judith A. Siuciak et al.
NEUROPHARMACOLOGY (2006)
Forebrain D1 function and sensorimotor gating in rats: Effects of D1 blockade, frontal lesions and dopamine denervation
NR Swerdlow et al.
NEUROSCIENCE LETTERS (2006)
Reduced startle gating after D1 blockade: Effects of concurrent D2 blockade
NR Swerdlow et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2005)
Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle
M Bortolato et al.
NEUROPSYCHOPHARMACOLOGY (2005)
PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats
JS Rodefer et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2005)
Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: Comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice
RJ Ralph et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Role of basolateral amygdala dopamine in modulating prepulse inhibition and latent inhibition in the rat
CW Stevenson et al.
PSYCHOPHARMACOLOGY (2004)
Half a century of antipsychotics and still a central role for dopamine D2 receptors
S Kapur et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Immunohistochemical localization of PDE10A in the rat brain
TF Seeger et al.
BRAIN RESEARCH (2003)
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
DC Goff et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies
DL Braff et al.
PSYCHOPHARMACOLOGY (2001)
Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity?
AM Ouagazzal et al.
PSYCHOPHARMACOLOGY (2001)
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review
MA Geyer et al.
PSYCHOPHARMACOLOGY (2001)
Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence
A Carlsson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Share Paper
